Abivax(US:ABVX) Ge Long Hui·2025-12-29 09:23Core Viewpoint - Biotech company Abivax (ABVX.US) saw a pre-market increase of 3.58%, reaching $147.4, following an upgrade from Guggenheim, which raised the target price from $150 to $175 and maintained a "Buy" rating based on optimistic expectations for its core drug obefazimod's upcoming data release [1]. Stock Performance - The closing price on December 26 was $142.31, reflecting a decrease of 2.06% [1] - The pre-market price on December 29 was $147.4, an increase of $5.09 [1] - The stock reached a high of $144.89 and a low of $139.42 during the trading session [1] - The average price was $141.665, with a trading volume of 665,100 shares [1] Financial Metrics - The total market capitalization of Abivax is approximately $11.09 billion [1] - The total share count is 77.93 million, with a circulating value of $5.98 billion [1] - The price-to-earnings ratio is currently at a loss, and the price-to-book ratio is 18.431 [1] Historical Performance - The stock has a 52-week high of $148.83 and a low of $4.77 [1] - The historical highest price recorded is $148.83, while the lowest is $4.77 [1]